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Too long for translocation?
P
eptides that are made too quickly can’t get into the 
ER, say Asvin Lakkaraju, Katharina Strub (University 
of Geneva, Switzerland), and colleagues. It seems 
that the peptides become too long for the translocation ma-
chinery to deal with.
The signal sequence at the amino terminal of a growing 
peptide chain is required for translocating the peptide into the 
ER. The signal sequence binds a signal recognition particle 
(SRP), which in turn binds to an SRP receptor on the endoplasmic 
reticulum and guides the nascent chain to a translocon—a channel 
that feeds the new peptides into the ER. Mammalian SRP has 
been known to delay elongation in vitro, but the signiﬁ  cance of 
the delay, and its occurrence in vivo, was unknown.
To explore SRP’s role in vivo, the authors prepared a 
mutated version of human SRP14 that speciﬁ  cally lacked the 
delaying function. SRP14’s ability to bind to nascent pep-
tides and to the SRP receptor remained intact. In cells that 
carried the mutant SRP, elongation sped up, but the ﬁ   nal 
concentration of secreted protein dropped and growth suf-
fered. Closer inspection revealed that translocation in these 
cells had slowed down and nascent peptide chains were be-
ing degraded.
The effects of mutant 
SRP could be mitigated with 
antibiotics that slowed elon-
gation. They could also be 
mitigated by increasing the 
number of SRP receptor mol-
ecules. Together, the data 
suggest that overly long pep-
tides, produced as a result 
of faster elongation, can still 
bind to the SRP receptor 
but do so unproductively—
perhaps by inhibiting the re-
ceptor’s ability to engage 
with the translocon.
Translation elongation, 
it appears, has the ability to 
go at a much faster pace than the normal cellular translocation 
machinery can cope with, and thus requires SRP to put the 
brakes on. Why elongation has evolved to be so super speedy, 
however, is not yet clear.
Lakkaraju, A.K.K., et al. 2008. Cell. 133:440–451.
Tumor cells share oncogenic receptors
M
utant receptors made in one tumor cell can be passed to tumor cells lacking them, say Khalid Al-Nedawi, 
Janusz Rak (McGill University, Montreal), and colleagues, increasing oncogenicity of the entire tumor.
In a certain type of human brain cancer called glioma, the gene encoding epidermal growth 
factor receptor is often mutated, creating a version of the receptor that is truncated and overactive. The presence 
of this mutant version, called EGFRvIII, can signify a more aggressive disease state, even if many cells in the 
tumor don’t express the receptor gene. Expressing and nonexpressing cells both display the mutant protein, 
however, and both contribute to malignancy. “It was hard to under-
stand how receptor expression in one small set of cells could upgrade 
the entire tumor” to the more aggressive form, Rak says.
The authors found that glioma cells expressing EGFRvIII trans-
ferred this errant receptor to nonexpressing cells via microvesicles—
small plasma membrane buds. The microvesicles were produced in 
abundance by the mutant expressing cells and were widely taken up by 
receptor-negative cells. Within 24 hours, these recipient cells had 
increased receptor-triggered downstream signaling and, compared 
with cells without receptors, could form twice as many colonies in 
agar—a standard sign of increased malignancy.
“We propose there is a much greater level of communication 
between cancer cells than is usually appreciated,” Rak says. Micro-
vesicles aren’t just shared among cells; previous work has shown that 
they’re also shed into the bloodstream. The fi  nding that glioma cells 
are sending out microvesicles could therefore potentially lead to a less 
invasive means of brain tumor characterization.
Al-Nedawi, K., et al. 2008. Nat. Cell Biol. doi:10.1038/ncb1725.
SRP (light green) targets nascent 
chains via the SRP receptor (blue) 
to the translocon (orange) for 
translocation into the ER. Chains 
that become too long before 
translocation are degraded.
Microvesicles (bright dots) containing mutant receptor are 
shed by glioma cells.
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